Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol for Neuroprotection in Neonates with CCHD
NCT04217421Phase 3Recruiting
- Start
- Feb 2020
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of allopurinol in Critical congenital heart disease (CCHD). Started Feb 2020; status: recruiting.
02
Drugs
allopurinol
03
Conditions
Critical congenital heart disease (CCHD)
Beyond the preview
Go deeper on NCT04217421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04217421.